secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2022-12-21T23:59:59+00:00
Accession:  0001493152-22-036068
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte sells 70% of Razor Genomics, cuts >40% workforce, eliminates COO and CSO roles
--------------------------------------------------------------------------------

- Sold 70% of Razor Genomics (DetermaRx) to Dragon Scientific, retains 30% equity; eliminates DetermaRx development and commercialization costs.
- Reduction in force of over 40% of full-time employees; expects annualized headcount cost savings of ~$10M, severance costs ~$1M.
- President/COO Gisela Paulsen and CSO Douglas Ross positions eliminated; Paulsen receives $207,500 severance, Ross receives $281,250 plus consulting through March 2023.
- Closing conditions include mutually acceptable royalty arrangement with former Razor shareholders; expected close not specified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222036068/0001493152-22-036068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222036068/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-036068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer